Huons said that it would market Gencurix's COVID-19 detection kit at both home and abroad.

Huons CEO Um Key-an (left) and Gencurix CEO Cho Sang-rae hold up their agreement at Huons headquarters in Seongnam, Gyeonggi Province, on Wednesday.

Gencurix's GenePro COVID19 Detection Test, licensed by Huons, is a gene amplification-based PCR (polymerase chain reaction) kit for diagnosing COVID-19 infection made under the World Health Organization guidelines.

According to Huons, the diagnostic kit of Gencurix has high specificity and sensitivity, and quickly sorts out diagnosis errors.

Application for the emergency use approval of the kit is underway at the Korea Centers for Disease Control and Prevention (KCDC). It is also in the approval process for its new diagnostic kit in the EU and expects to receive CE-IVD (CE In-vitro Diagnostic Device) certification by next week to facilitate the supply of diagnostic kits worldwide.

After completing CE-IVD registration, Huons will export the kit to many countries, including Southeast Asia, Oceania and the Middle East, as well as Europe.

Huons is actively negotiating with its global partners so that the diagnostic kit can quickly reach the export path.

"Gencurix is a company that has accumulated technology for a long time in the field of in-vitro diagnostics in partnership with Huons to accelerate its entry into the global market," Gencurix CEO Cho Sang-rae said. "We will do our best to supply improved COVID-19 diagnostic kits to the global market."

Huons CEO Um Key-an also said, "Huons is a leader in the domestic pharmaceutical industry for more than 50 years and has extensive experience in entering the global market as it exports pharmaceuticals and medical devices to over 50 countries."

The company, armed with a global network, will rapidly supply COVID-19 diagnostic kits to the world and lead the way in preventing the product’s supply shortage, Um added.

corea022@docdocdoc.co.kr

<© Korea Biomedical Review, All rights reserved.>